DEAR VISITORS, THE NEW WEBSITE IS UNDER CONSTRUCTION, SO WE ASK FOR YOUR UNDERSTANDING IF YOU ENCOUNTER OUT-OF-DATE OR INCORRECT INFORMATION. FOR ALL QUESTIONS, WE ARE AT YOUR DISPOSAL BY PHONE +38131597597 or e-mail address: office@cigota.rs
DEAR VISITORS, THE NEW WEBSITE IS UNDER CONSTRUCTION, SO WE ASK FOR YOUR UNDERSTANDING IF YOU ENCOUNTER OUT-OF-DATE OR INCORRECT INFORMATION. FOR ALL QUESTIONS, WE ARE AT YOUR DISPOSAL BY PHONE +38131597597 or e-mail address: office@cigota.rs
WILSON S DISEASE
ABSTRACT The Wilson s disease ( WD) gene is located on chromosomu 13. Deficiency of the WD gene product is likely to be responsible for the lack of copper incorporation into ceruloplasmin and the defective biliary excretion of copper in WD. The majority of symptomatic WD patients present with hepatic or neuropsychiatric features; the principal hepatic manifestacions include fulminant hepatic failure, chronic hepatitis, and cirrhosis. In patients with a low serum ceruloplazmin, diagnosis of WD in the absence of Kayser-Fleischer rings requires determination of hepatic copper concetration. Serum detection of radiocopper incorporation into ceruloplazmin may be a useful alternative test when liver biopsy is contraindicated. The use of DNA marker studies is limited largely to genetic screening of young family members of difficult diagnostic situations, using the index patients DNA as a reference. The drug of choice for treating WD patients is D-penicillamine, but alternatives under selected circumstances include, zinc, or tetrathiomolybdate. Liver transplantation is indicated for patients with fulminant hepatitis or decompensated cirrhosis unresponsive to therapy.
Attachment | Size |
---|---|
Glasnik 3 E 7.pdf | 14.05 KB |